Trump Abandons ‘FDA for AI’ Proposal

https://www.techpolicy.press/trump-abandons-fda-for-ai-proposal

Publish Date: 2026-05-22 17:33:00

Here’s a summary of the key points from the article, provided in an unordered list:

– President Donald Trump announced his AI Action Plan and planned to sign executive orders related to artificial intelligence and cybersecurity.
– The executive order was postponed by Trump, who feared it might hinder U.S. technological leadership, particularly in AI.
– Notably, executives from major AI laboratories received last-minute invitations to attend the signing ceremony, which was later postponed.
– Leading tech figures, including Mark Zuckerberg, Elon Musk, and David Sacks, had prior conversations with Trump influencing his decision.
– The leaked draft of the executive order emphasized voluntariness, with companies having the choice to share models and no mandatory governmental licensing.
– The document included measures like creating a clearinghouse for sharing cybersecurity vulnerabilities and hiring more cyber staff, but notably directed the Attorney General to enforce cybersecurity laws against misuse of AI.
– There was a significant rift regarding the role and control of AI model evaluations, with intelligence agencies pushing for classified evaluations and civilian regulators advocating for more public accountability.
– The National Security Agency (NSA) was given the power to conduct confidential evaluations of AI models, suggesting a shift away from more transparent civilian AI governance frameworks.
– Trump’s postponed executive order revealed an intelligence-community-led approach to AI evaluation, sidelining civilian regulators and maintaining secrecy around key decisions.
– AI lobbyists and industry leaders continued to have significant informal influence in shaping policy behind the scenes, while public deliberation and transparency took a back seat.
– The article discusses how the resulting governance structure lacks the public accountability or statutory foundation typically present in civilian regulatory approaches like those of the FDA.

This summary encapsulates the article’s key theme of balancing innovation with governance, revealing the complex interplay between technology, policy, and interests from both governmental and private sectors.